Arkolith/Insider Trading/VIR/Form 4

Sabatini Brent

SVP, Chief Accounting OfficerVir Biotechnology, Inc. (VIR) · full profile →Form 4 · filed Feb 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$14K
Net Open-Market Flow
-$14K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 23, 2026Sell(S)2K$7.45$14K71K
Feb 22, 2026Grant(A)25K—$073K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 22, 2026Grant(A)50K—$050K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-011331) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML